Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study
暂无分享,去创建一个
P W Macfarlane | S M Cobbe | I Ford | J Norrie | J Shepherd | P. Macfarlane | J. Norrie | I. Ford | C. Packard | N. Sattar | D. Freeman | J. Shepherd | S. Cobbe | C. Isles | J. Mckillop | A. Gaw | N Sattar | J H McKillop | R. Neely | C J Packard | A. Lorimer | A R Lorimer | D J Freeman | R D Neely | C Isles | A Gaw
[1] David Collett. Modelling Survival Data in Medical Research , 1994 .
[2] J. Meigs,et al. Metabolic Risk Factors Worsen Continuously across the Spectrum of Nondiabetic Glucose Tolerance: The Framingham Offspring Study , 1998, Annals of Internal Medicine.
[3] Daniel L. McGee,et al. Obesity, very low density lipoproteins, and glucose intolerance over fourteen years: The Framingham Study. , 1981, American journal of epidemiology.
[4] S. Coppack,et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[5] A. Cerami,et al. Lipoprotein lipase suppression in 3T3-L1 cells by an endotoxin-induced mediator from exudate cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[6] HOMAS,et al. The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .
[7] J. Muramatsu,et al. Hemodynamic changes associated with reduction in total cholesterol by treatment with the HMG-CoA reductase inhibitor pravastatin. , 1997, Atherosclerosis.
[8] T. Ishizaki,et al. Effects of Provastatin, a 3-hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitor, on Glucose Tolerance in Patients With Essential Hypertension , 1993, Diabetes Care.
[9] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.
[10] Ames,et al. PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .
[11] P. Macfarlane,et al. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. , 1999, The American journal of cardiology.
[12] J. T. ter Maaten,et al. Microvascular function relates to insulin sensitivity and blood pressure in normal subjects. , 1999, Circulation.
[13] P. Macfarlane,et al. SCREENING EXPERIENCE AND BASE-LINE CHARACTERISTICS IN THE WEST OF SCOTLAND CORONARY PREVENTION STUDY , 1995 .
[14] M. Taskinen,et al. Decreasing triglyceride by gemfibrozil therapy does not affect the glucoregulatory or antilipolytic effect of insulin in nondiabetic subjects with mild hypertriglyceridemia. , 1995, Metabolism: clinical and experimental.
[15] P. Libby,et al. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. , 1998, Journal of the American College of Cardiology.
[16] J. Girard,et al. Is leptin the link between obesity and insulin resistance? , 1997, Diabetes & metabolism.
[17] P. Raskin,et al. Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.
[18] B. Spiegelman,et al. IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNF-α- and Obesity-Induced Insulin Resistance , 1996, Science.
[19] K. Feingold,et al. Effects of endotoxin and cytokines on lipid metabolism. , 1994, Current opinion in lipidology.
[20] W. Sheu,et al. Effect of pravastatin treatment on glucose, insulin, and lipoprotein metabolism in patients with hypercholesterolemia. , 1994, American heart journal.
[21] Gerardo Heiss,et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study , 1999, The Lancet.
[22] L. Yeatman,et al. Effect of pravastatin on outcomes after cardiac transplantation. , 1995, The New England journal of medicine.
[23] B. Davis,et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. , 1998, Circulation.
[24] D. Collet. Modelling Survival Data in Medical Research , 2004 .
[25] T. Ishizaki,et al. Effects of pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on glucose tolerance in patients with essential hypertension. , 1993, Diabetes care.
[26] J. A. McCarthy,et al. Is the Traditional Alcohol Wipe Necessary Before an Insulin Injection?: Dogma disputed , 1993, Diabetes Care.
[27] S. Haffner,et al. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? , 1990, JAMA.
[28] Roger A. Renfrew,et al. Lipid Research Clinics Program. , 1984, JAMA.
[29] K. Uysal,et al. Protection from obesity-induced insulin resistance in mice lacking TNF-α function , 1997, Nature.
[30] M. Sugimachi,et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. , 1994, Circulation.
[31] R. Rosenson,et al. Inhibition of proinflammatory cytokine production by pravastatin , 1999, The Lancet.
[32] C. Lau,et al. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients , 1993, The Lancet.